|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||
| Cash and due from banks | ||||||||||||||
| Interest-earning deposits with banks | ||||||||||||||
| Cash and cash equivalents | ||||||||||||||
| Securities available-for-sale, at fair value | ||||||||||||||
| Restricted stock, at cost | ||||||||||||||
| Loans held-for-sale | ||||||||||||||
| Loans | ||||||||||||||
| Allowance for credit losses | ||||||||||||||
| Net loans | ||||||||||||||
| Other real estate owned | ||||||||||||||
| Premises and equipment, net | ||||||||||||||
| Accrued interest receivable | ||||||||||||||
| Intangible assets | ||||||||||||||
| Goodwill | ||||||||||||||
| Company-owned life insurance | ||||||||||||||
| Other assets | ||||||||||||||
| Total Assets | ||||||||||||||
| Liabilities and Shareholders’ Equity | ||||||||||||||
| Liabilities | ||||||||||||||
| Non-interest-bearing deposits | ||||||||||||||
| Interest-bearing deposits | ||||||||||||||
| Total deposits | ||||||||||||||
| Borrowed funds | ||||||||||||||
| Short-term borrowings | ||||||||||||||
| Subordinated debentures, net | ||||||||||||||
| Subordinated debentures owed to unconsolidated subsidiary trusts | ||||||||||||||
| Accrued interest and other liabilities | ||||||||||||||
| Total Liabilities | ||||||||||||||
| Shareholders’ Equity | ||||||||||||||
| Preferred stock and related surplus, $1.00 par value per share; 2,000,000 shares authorized; 1,500 shares issued and outstanding at June 30, 2026; 1,500 shares issued and outstanding at December 31, 2025 | ||||||||||||||
| Common Stock $0.50 par value; 40,000,000 shares authorized, 20,736,461 shares issued and 20,165,171 shares outstanding at June 30, 2026; 40,000,000 shares authorized, 15,599,814 shares issued and 15,028,524 shares outstanding at December 31, 2025 | ||||||||||||||
| Additional paid-in capital | ||||||||||||||
| Common stock, additional paid-in capital | ||||||||||||||
| Retained earnings | ||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||
| Treasury stock 571,290 shares, at cost, at September 30, 2025, and 571,290 shares, at cost, at December 31, 2024 | ||||||||||||||
| Total Shareholders’ Equity | ||||||||||||||
| Total Liabilities and Shareholders’ Equity | ||||||||||||||
Loading...
